

General description

Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.

INN	Doxorubicin
ATC codes	L01DB01 L01AA01
Medicine type	Chemical agent
EML status history	<p>First added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2011 (TRS 965) for Lymphoid leukaemia, not elsewhere classified Added in 2011 (TRS 965) for Burkitt lymphoma including Burkitt leukaemia Added in 2015 (TRS 994) for Follicular lymphoma Added in 2015 (TRS 994) for Malignant neoplasms of breast Added in 2015 (TRS 994) for Hodgkin lymphoma Added in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site Added in 2015 (TRS 994) for Diffuse large B-cell lymphomas Added in 2015 (TRS 994) for Malignant neoplasms of kidney, except renal pelvis Added in 2015 (TRS 994) for Ewing sarcoma of bone and articular cartilage of unspecified sites Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of unspecified sites Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2015 (TRS 994) for Other specified malignant neoplasms of breast Added in 2019 (TRS 1021) for Plasma cell myeloma Application rejected in 2021 (TRS 1035) for Rhabdomyosarcoma primary site Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative</p>
Wikipedia	Doxorubicin ↗
DrugBank	Doxorubicin ↗

Recommendations

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Diffuse large B-cell lymphomas

Malignant neoplasms of breast

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Follicular lymphoma

Unspecified malignant neoplasms of ill-defined or unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of kidney, except renal pelvis

Burkitt lymphoma including Burkitt leukaemia

Other specified malignant neoplasms of breast

Plasma cell myeloma

Rhabdomyosarcoma primary site

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

